Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENDP NASDAQ:INVA NASDAQ:MDGL NASDAQ:TBPH NASDAQ:ZEAL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENDPEndo International$0.45$0.28▼$7.07$141K1.1528.19 million shs9,967 shsINVAInnoviva$19.55+0.9%$19.61$16.67▼$22.00$1.23B0.47813,962 shs767,862 shsMDGLMadrigal Pharmaceuticals$425.60-1.5%$364.11$200.63▼$457.16$9.45B-1.02378,165 shs265,385 shsTBPHTheravance Biopharma$14.40+0.7%$12.46$7.88▼$14.55$725.20M0.05294,328 shs447,517 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENDPEndo International0.00%0.00%0.00%0.00%0.00%INVAInnoviva0.00%-5.42%-7.41%-11.15%-2.22%MDGLMadrigal Pharmaceuticals0.00%-0.15%+16.87%+51.62%+78.75%TBPHTheravance Biopharma0.00%+2.51%+8.75%+33.02%+75.68%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENDPEndo International$0.45$0.28▼$7.07$141K1.1528.19 million shs9,967 shsINVAInnoviva$19.55+0.9%$19.61$16.67▼$22.00$1.23B0.47813,962 shs767,862 shsMDGLMadrigal Pharmaceuticals$425.60-1.5%$364.11$200.63▼$457.16$9.45B-1.02378,165 shs265,385 shsTBPHTheravance Biopharma$14.40+0.7%$12.46$7.88▼$14.55$725.20M0.05294,328 shs447,517 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENDPEndo International0.00%0.00%0.00%0.00%0.00%INVAInnoviva0.00%-5.42%-7.41%-11.15%-2.22%MDGLMadrigal Pharmaceuticals0.00%-0.15%+16.87%+51.62%+78.75%TBPHTheravance Biopharma0.00%+2.51%+8.75%+33.02%+75.68%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENDPEndo International 0.00N/AN/AN/AINVAInnoviva 3.00Buy$42.75118.67% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$483.3813.57% UpsideTBPHTheravance Biopharma 3.60Strong Buy$23.0059.72% UpsideZEALZealand Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ENDP, MDGL, ZEAL, TBPH, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$428.00 ➝ $526.009/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/4/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$500.008/26/2025MDGLMadrigal PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/26/2025MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$390.00 ➝ $554.008/20/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$483.00 ➝ $485.008/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/12/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$458.00 ➝ $523.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.008/11/2025INVAInnovivaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENDPEndo International$2.99B0.00N/A0.06($13.60) per share0.00INVAInnoviva$358.71M3.43$3.46 per share5.65$11.03 per share1.77MDGLMadrigal Pharmaceuticals$180.13M52.45N/AN/A$34.59 per share12.30TBPHTheravance Biopharma$77.21M9.39N/AN/A$3.57 per share4.03ZEALZealand Pharma A/S$46.54M17.59N/AN/A$3.38 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENDPEndo International-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/AINVAInnoviva$23.39M$0.3163.0712.61N/A10.44%18.67%9.92%11/5/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)TBPHTheravance Biopharma-$56.42M$0.2460.0041.14N/A16.88%6.93%3.52%11/11/2025 (Estimated)ZEALZealand Pharma A/S-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/ALatest ENDP, MDGL, ZEAL, TBPH, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/5/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENDPEndo InternationalN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENDPEndo InternationalN/A1.861.62INVAInnoviva0.362.642.44MDGLMadrigal Pharmaceuticals0.175.114.78TBPHTheravance BiopharmaN/A6.706.70ZEALZealand Pharma A/S0.934.794.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENDPEndo International80.39%INVAInnoviva99.12%MDGLMadrigal Pharmaceuticals98.50%TBPHTheravance Biopharma99.10%ZEALZealand Pharma A/S1.73%Insider OwnershipCompanyInsider OwnershipENDPEndo International1.20%INVAInnoviva2.25%MDGLMadrigal Pharmaceuticals21.50%TBPHTheravance Biopharma6.90%ZEALZealand Pharma A/S2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENDPEndo International3,103235.14 million232.32 millionNo DataINVAInnoviva10063.02 million61.60 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableZEALZealand Pharma A/S35546.54 million45.51 millionNot OptionableENDP, MDGL, ZEAL, TBPH, and INVA HeadlinesRecent News About These CompaniesZealand Pharma increases its share capital as a result of the exercise of employee warrantsSeptember 11, 2025 | globenewswire.comSAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025September 11, 2025 | globenewswire.comZealand Pharma to participate in upcoming investor conferences in September 2025August 28, 2025 | globenewswire.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.August 20, 2025 | globenewswire.comQ2 2025 Zealand Pharma A/S Earnings Call TranscriptAugust 14, 2025 | gurufocus.comZealand Pharma Announces Financial Results for the First Half of 2025August 14, 2025 | globenewswire.comZealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial resultsAugust 7, 2025 | globenewswire.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.July 18, 2025 | markets.businessinsider.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.July 18, 2025 | globenewswire.comZealand Pharma A/S. (ZLDPF) Institutional Holdings | NasdaqJuly 11, 2025 | nasdaq.comZealand Pharma A/S. (ZLDPF) Analyst Research | NasdaqJuly 11, 2025 | nasdaq.comStock Movers: Sainsbury's, Zealand Pharma, Taylor WimpeyJuly 1, 2025 | bloomberg.comZealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for MoreJune 20, 2025 | biospace.comBPositive results for Zealand’s GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | thepharmaletter.comTProthena to lay off majority of staff; Zealand shares obesity drug dataJune 20, 2025 | biopharmadive.comBZealand Pharma’s 46% Stock Slump Makes New Obesity Drug CriticalJune 20, 2025 | bloomberg.comZealand Pharma announces positive topline results from phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | pharmabiz.comPZealand’s GLP-2 candidate shows early weight loss resultsJune 18, 2025 | statnews.comSZealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeksJune 18, 2025 | fiercebiotech.comFZealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENDP, MDGL, ZEAL, TBPH, and INVA Company DescriptionsEndo International NASDAQ:ENDPEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.Innoviva NASDAQ:INVA$19.55 +0.18 (+0.93%) Closing price 04:00 PM EasternExtended Trading$19.55 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Madrigal Pharmaceuticals NASDAQ:MDGL$425.60 -6.62 (-1.53%) Closing price 04:00 PM EasternExtended Trading$425.47 -0.13 (-0.03%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Theravance Biopharma NASDAQ:TBPH$14.40 +0.10 (+0.70%) Closing price 04:00 PM EasternExtended Trading$14.40 +0.00 (+0.03%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Zealand Pharma A/S NASDAQ:ZEALZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
